Predictions
Cathay General Bancorp
Start price
Target price
Perf. (%)
€32.80
30.09.23
30.09.23
-
30.09.24
30.09.24
17.49%
21.08.24
21.08.24
Enanta Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€10.70
30.09.23
30.09.23
-
30.09.24
30.09.24
3.74%
21.08.24
21.08.24
Powell Industries Inc.
Start price
Target price
Perf. (%)
€78.50
30.09.23
30.09.23
-
30.09.24
30.09.24
99.46%
22.08.24
22.08.24
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€0.14
30.09.23
30.09.23
-
30.09.24
30.09.24
-
08.09.23
08.09.23
Clearside Biomedical Inc
Start price
Target price
Perf. (%)
€0.81
30.09.23
30.09.23
-
30.09.24
30.09.24
9.32%
21.08.24
21.08.24
Shenandoah Telecommunications Co.
Start price
Target price
Perf. (%)
€19.30
30.09.23
30.09.23
-
30.09.24
30.09.24
-34.28%
21.08.24
21.08.24
Protagonist Therapeutics Inc
Start price
Target price
Perf. (%)
€21.80
30.09.23
30.09.23
-
30.09.24
30.09.24
-
24.02.22
24.02.22
Roivant Sciences Ltd.
Start price
Target price
Perf. (%)
€10.50
30.09.23
30.09.23
€5.00
30.09.24
30.09.24
-9.52%
14.10.23
14.10.23
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Low dividend yield expected
Bad rating
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€1.64
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-9.76%
14.10.23
14.10.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Mithra Pharmaceuticals S.A.
Start price
Target price
Perf. (%)
€1.40
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-21.00%
14.10.23
14.10.23
Probably not worthwhile Investment
Bad rating
Little Investments for future growth
Risky balance sheet
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€19.60
30.09.23
30.09.23
€9.00
30.09.24
30.09.24
11.22%
14.10.23
14.10.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Capricor Therapeutics Inc
Start price
Target price
Perf. (%)
€3.32
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-17.17%
14.10.23
14.10.23
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected